Your browser version may not work well with NCBI's Web applications. More information here...
1: IDrugs. 2000 May;3(5):496-8.Links

New trends in clinical and experimental immunosuppression--fourth international conference. 17-20 February 2000, Geneva, Switzerland.

Adorini L.

Roche Milano Ricerche, Via Olgettina 58, 20132, Milano, Italy. luciano.adorini@roche.com

The meeting covered several aspects of currently used immunosuppressive drugs, but focused on tolerance induction strategies in the treatment of both allograft rejection and autoimmune diseases. Topics discussed included: clinical trials with anti-CD3 in recently-diagnosed insulin-dependent diabetes mellitus (IDDM) patients; Tr1 cells in bone-marrow transplantation; and, 1 alpha,25-dihydroxyvitamin D3-associated with mycophenolate mofetil and anti-CD25 in islet transplantation. In addition, malononitrilamides, an emerging class of novel immunosuppressants, were discussed in depth.

PMID: 16100680 [PubMed]

Patient Drug Information

  • Mycophenolate (CellCept® , Myfortic® )

    Mycophenolate (CellCept) is used with other medications to help prevent transplant organ rejection (attack of the transplanted organ by the immune system of the person receiving the organ) in people who have received kid...

  • Source: AHFS Consumer Medication Information